MDMA for Co-occurring PTSD and OUD After Childbirth

This open-label trial (n=15) will assess the effectiveness of MDMA-assisted therapy (MDMA-AT) for individuals experiencing both Post Traumatic Stress Disorder (PTSD) and Opioid Use Disorder (OUD) in the postpartum period.

Conducted by the University of New Mexico, the study aims to explore the feasibility and safety of using MDMA-AT to treat PTSD in this population. Participants must be at least 18 years old, have stable opioid use for at least three months, and meet specific criteria for PTSD and OUD.

The primary outcome measure will be PTSD severity assessed by the CAPS-5 four weeks after the third experimental session. Secondary outcomes include assessing opioid use disorder using the Timeline Follow-Back six months after the third experimental session. The study is anticipated to start in March 2024 and conclude in November 2025.

Topic Postpartum Depression PTSD Opioid Use Disorder
Compound MDMA
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of New Mexico
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.